vs

Side-by-side financial comparison of Assertio Holdings, Inc. (ASRT) and Eagle Bancorp Montana, Inc. (EBMT). Click either name above to swap in a different company.

Eagle Bancorp Montana, Inc. is the larger business by last-quarter revenue ($24.3M vs $13.5M, roughly 1.8× Assertio Holdings, Inc.). On growth, Eagle Bancorp Montana, Inc. posted the faster year-over-year revenue change (13.7% vs -57.9%). Over the past eight quarters, Eagle Bancorp Montana, Inc.'s revenue compounded faster (12.6% CAGR vs -35.4%).

Assertio Therapeutics, Inc. is an American specialty pharmaceutical company. It mainly markets products for treatment in neurology, pain and diseases of the central nervous system. Depomed was founded in 1995 and is headquartered in Newark, California. It is a publicly traded company on NASDAQ, with several products approved by the United States Food and Drug Administration (FDA). On August 15, 2018, the company announced its name change from Depomed, Inc., to Assertio Therapeutics, Inc. As o...

U.S. Bancorp is an American multinational banking institution headquartered in Minneapolis, Minnesota and incorporated in Delaware. It is the 5th-largest bank in the United States as of 2025. As the largest bank in the Midwestern United States, it is considered systemically important by the Financial Stability Board. It is the parent company of its primary operating entity, U.S. Bank National Association, which does business as U.S. Bank. The company provides banking, investment, mortgage, tr...

ASRT vs EBMT — Head-to-Head

Bigger by revenue
EBMT
EBMT
1.8× larger
EBMT
$24.3M
$13.5M
ASRT
Growing faster (revenue YoY)
EBMT
EBMT
+71.6% gap
EBMT
13.7%
-57.9%
ASRT
Faster 2-yr revenue CAGR
EBMT
EBMT
Annualised
EBMT
12.6%
-35.4%
ASRT

Income Statement — Q4 FY2025 vs Q4 FY2025

Metric
ASRT
ASRT
EBMT
EBMT
Revenue
$13.5M
$24.3M
Net Profit
$4.7M
Gross Margin
Operating Margin
-86.7%
25.0%
Net Margin
19.5%
Revenue YoY
-57.9%
13.7%
Net Profit YoY
37.8%
EPS (diluted)
$-4.54
$0.62

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
ASRT
ASRT
EBMT
EBMT
Q4 25
$13.5M
$24.3M
Q3 25
$49.5M
$23.4M
Q2 25
$29.2M
$23.0M
Q1 25
$26.5M
$20.9M
Q4 24
$32.2M
$21.4M
Q3 24
$29.2M
$20.8M
Q2 24
$31.1M
$19.9M
Q1 24
$32.4M
$19.2M
Net Profit
ASRT
ASRT
EBMT
EBMT
Q4 25
$4.7M
Q3 25
$11.4M
$3.6M
Q2 25
$-16.4M
$3.2M
Q1 25
$-13.5M
$3.2M
Q4 24
$3.4M
Q3 24
$-2.9M
$2.7M
Q2 24
$-3.7M
$1.7M
Q1 24
$-4.5M
$1.9M
Operating Margin
ASRT
ASRT
EBMT
EBMT
Q4 25
-86.7%
25.0%
Q3 25
23.2%
21.2%
Q2 25
-27.5%
17.4%
Q1 25
-50.0%
18.5%
Q4 24
-41.9%
17.3%
Q3 24
-10.4%
15.6%
Q2 24
-11.6%
11.0%
Q1 24
-13.4%
11.8%
Net Margin
ASRT
ASRT
EBMT
EBMT
Q4 25
19.5%
Q3 25
23.1%
15.5%
Q2 25
-56.0%
14.1%
Q1 25
-51.1%
15.5%
Q4 24
16.1%
Q3 24
-10.0%
13.0%
Q2 24
-11.8%
8.7%
Q1 24
-13.9%
9.9%
EPS (diluted)
ASRT
ASRT
EBMT
EBMT
Q4 25
$-4.54
$0.62
Q3 25
$0.11
$0.46
Q2 25
$-0.17
$0.41
Q1 25
$-0.14
$0.41
Q4 24
$-3.28
$0.44
Q3 24
$-0.03
$0.34
Q2 24
$-0.04
$0.22
Q1 24
$-0.05
$0.24

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
ASRT
ASRT
EBMT
EBMT
Cash + ST InvestmentsLiquidity on hand
$63.4M
$63.0M
Total DebtLower is stronger
$44.5M
Stockholders' EquityBook value
$94.0M
$191.8M
Total Assets
$267.0M
$2.1B
Debt / EquityLower = less leverage
0.23×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
ASRT
ASRT
EBMT
EBMT
Q4 25
$63.4M
$63.0M
Q3 25
$93.4M
$29.5M
Q2 25
$98.2M
$26.9M
Q1 25
$87.3M
$22.8M
Q4 24
$100.1M
$31.6M
Q3 24
$88.6M
$42.2M
Q2 24
$88.4M
$23.8M
Q1 24
$80.7M
$20.9M
Total Debt
ASRT
ASRT
EBMT
EBMT
Q4 25
$44.5M
Q3 25
$59.3M
Q2 25
$59.2M
Q1 25
$59.2M
Q4 24
$59.1M
Q3 24
$59.1M
Q2 24
$59.1M
Q1 24
$38.6M
$59.0M
Stockholders' Equity
ASRT
ASRT
EBMT
EBMT
Q4 25
$94.0M
$191.8M
Q3 25
$105.8M
$186.5M
Q2 25
$93.3M
$180.6M
Q1 25
$108.5M
$177.6M
Q4 24
$121.1M
$174.8M
Q3 24
$130.5M
$177.7M
Q2 24
$132.2M
$170.2M
Q1 24
$134.5M
$168.9M
Total Assets
ASRT
ASRT
EBMT
EBMT
Q4 25
$267.0M
$2.1B
Q3 25
$319.8M
$2.1B
Q2 25
$273.8M
$2.1B
Q1 25
$286.4M
$2.1B
Q4 24
$284.7M
$2.1B
Q3 24
$276.0M
$2.1B
Q2 24
$279.4M
$2.1B
Q1 24
$282.0M
$2.1B
Debt / Equity
ASRT
ASRT
EBMT
EBMT
Q4 25
0.23×
Q3 25
0.32×
Q2 25
0.33×
Q1 25
0.33×
Q4 24
0.34×
Q3 24
0.33×
Q2 24
0.35×
Q1 24
0.29×
0.35×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
ASRT
ASRT
EBMT
EBMT
Operating Cash FlowLast quarter
$-30.0M
$33.1M
Free Cash FlowOCF − Capex
$28.3M
FCF MarginFCF / Revenue
116.7%
Capex IntensityCapex / Revenue
19.7%
Cash ConversionOCF / Net Profit
7.01×
TTM Free Cash FlowTrailing 4 quarters
$37.1M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
ASRT
ASRT
EBMT
EBMT
Q4 25
$-30.0M
$33.1M
Q3 25
$-4.8M
$9.0M
Q2 25
$19.1M
$1.7M
Q1 25
$-12.5M
$1.9M
Q4 24
$11.5M
$28.5M
Q3 24
$-35.0K
$2.6M
Q2 24
$7.4M
$3.3M
Q1 24
$7.5M
$7.1M
Free Cash Flow
ASRT
ASRT
EBMT
EBMT
Q4 25
$28.3M
Q3 25
$7.1M
Q2 25
$1.4M
Q1 25
$262.0K
Q4 24
$14.5M
Q3 24
$-749.0K
Q2 24
$627.0K
Q1 24
$2.3M
FCF Margin
ASRT
ASRT
EBMT
EBMT
Q4 25
116.7%
Q3 25
30.3%
Q2 25
6.0%
Q1 25
1.3%
Q4 24
67.7%
Q3 24
-3.6%
Q2 24
3.2%
Q1 24
12.2%
Capex Intensity
ASRT
ASRT
EBMT
EBMT
Q4 25
19.7%
Q3 25
8.0%
Q2 25
1.6%
Q1 25
7.8%
Q4 24
65.9%
Q3 24
0.0%
16.1%
Q2 24
13.3%
Q1 24
24.9%
Cash Conversion
ASRT
ASRT
EBMT
EBMT
Q4 25
7.01×
Q3 25
-0.42×
2.47×
Q2 25
0.54×
Q1 25
0.58×
Q4 24
8.31×
Q3 24
0.96×
Q2 24
1.88×
Q1 24
3.75×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

ASRT
ASRT

Products$12.8M95%
Other$719.0K5%

EBMT
EBMT

Other$13.2M54%
Commodity Sales$8.6M35%
Bank Servicing$2.6M11%

Related Comparisons